CXCR4 and neoplasm: The inclusion of CXCR4E was intended to block the suppressive pathway driven by cancer-associated fibroblast secretion of CXCL12, which binds CXCR4 on T cells to hinder their tumor engagement and dampen responsiveness to CXCL10.